Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | AURKA | O14965 | 1/20 | 0.48 |
| ▸ | GSK3A | P49840 | 1/20 | 0.48 |
| ▸ | GSK3B | P49841 | 1/20 | 0.48 |
| ▸ | NR3C2 | P08235 | 7/20 | 0.48 |
| ▸ | PIK3C3 | Q8NEB9 | 4/20 | 0.47 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | JAK1 | P23458 | 1/20 | 0.46 |
| ▸ | TYK2 | P29597 | 1/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 6/20 | 0.46 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL91333 | 0.85 | RIOK2 (0.57) | L3MBTL1AURKAGSK3AGSK3BNR3C2 | |
| SCHEMBL7671508 | 0.85 | L3MBTL1 (0.52) | L3MBTL1AURKAGSK3AGSK3BNR3C2 | |
| SCHEMBL501285 | 0.85 | L3MBTL1 (0.52) | L3MBTL1AURKAGSK3AGSK3BNR3C2 | |
| SCHEMBL29507273 | 0.85 | L3MBTL1 (0.52) | L3MBTL1AURKAGSK3AGSK3BNR3C2 | |
| SCHEMBL23015674 | 0.83 | NR3C2 (0.55) | L3MBTL1NR3C2PIK3C3MAPK14 | |
| SCHEMBL21847287 | 0.83 | L3MBTL1 (0.50) | L3MBTL1AURKAGSK3AGSK3BNR3C2 | |
| SCHEMBL30893838 | 0.83 | L3MBTL1 (0.50) | L3MBTL1AURKAGSK3AGSK3BNR3C2 | |
| SCHEMBL4309482 | 0.83 | L3MBTL1 (0.50) | L3MBTL1AURKAGSK3AGSK3BNR3C2 | |
| SCHEMBL2642714 | 0.83 | LOXL2 (0.58) | L3MBTL1AURKAGSK3AGSK3BNR3C2 | |
| Hydrochloric Acid SCHEMBL17161867 | 0.82 | L3MBTL1 (0.49) | L3MBTL1AURKAGSK3AGSK3BNR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8765789-B2 | 2-pyridinecarboxamide derivatives | MSD K.K. (JP) | 2014-07-01 | — | — | US | disclosed |
| US-20130085156-A1 | NOVEL 2-PYRIDINECARBOXAMIDE DERIVATIVES | MSD K.K. (JP) | 2013-04-04 | — | — | US | disclosed |
| US-8344003-B2 | 2-pyridinecarboxamide derivatives | MSD K. K. (JP) | 2013-01-01 | — | — | US | disclosed |
| US-20100041660-A1 | NOVEL 2-PYRIDINECARBOXAMIDE DERIVATIVES | MSD K.K. (JP) | 2010-02-18 | — | — | US | disclosed |
| US-7629362-B2 | 2-pyridine carboxamide derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-12-08 | — | — | US | disclosed |
| US-20060258701-A1 | Novel 2-pyridinecarboxamide derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-16 | — | — | US | disclosed |
| EP-1598349-A1 | NOVEL 2-PYRIDINECARBOXAMIDE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-11-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130085156-A1 | NOVEL 2-PYRIDINECARBOXAMIDE DERIVATIVES | GCKR, GCK, HK2 | L3MBTL1 4342/4885AURKA 3856/4885GSK3A 1926/4885 |
| US-20060258701-A1 | Novel 2-pyridinecarboxamide derivatives | GCKR, GCK, HK2 | L3MBTL1 4359/4885AURKA 3901/4885GSK3A 1871/4885 |
| US-20100041660-A1 | NOVEL 2-PYRIDINECARBOXAMIDE DERIVATIVES | GCKR, GCK, HK2 | L3MBTL1 4342/4885AURKA 3856/4885GSK3A 1926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.